POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Quick facts
Phase 3 pipeline
- [Lu-177]-PNT2002 · Oncology
[Lu-177]-PNT2002 is a lutetium-177 labeled radioligand that targets somatostatin receptor 2 (SSTR2) on neuroendocrine tumor cells, delivering targeted radiation therapy.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company portfolio CI brief
- POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company pipeline updates RSS
Frequently asked questions about POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
What is POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company's pipeline?
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include [Lu-177]-PNT2002.
Related
- Sector hub: All tracked pharma companies